A 28 week, randomized, double-blind, placebo-controlled, two-part, multicenter, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia (InvestiGAIT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimagrumab (Primary)
Indications Muscular atrophy
Focus Therapeutic Use
Acronyms InvestiGAIT
Sponsors Novartis Pharmaceuticals

Most Recent Events

05 Dec 2018 Status changed from recruiting to completed.
17 Aug 2018 Planned End Date changed from 13 Jan 2019 to 16 Oct 2018.
17 Aug 2018 Planned primary completion date changed from 16 Dec 2018 to 11 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight